211 related articles for article (PubMed ID: 25919182)
1. Tracking financial flows for immunization in Honduras.
Valdés W; Janusz CB; Molina Aguilera IB; Mendoza L; Díaz IY; Resch S
Vaccine; 2015 May; 33 Suppl 1():A85-92. PubMed ID: 25919182
[TBL] [Abstract][Full Text] [Related]
2. Examining the cost of delivering routine immunization in Honduras.
Janusz CB; Castañeda-Orjuela C; Molina Aguilera IB; Felix Garcia AG; Mendoza L; Díaz IY; Resch SC
Vaccine; 2015 May; 33 Suppl 1():A53-9. PubMed ID: 25919175
[TBL] [Abstract][Full Text] [Related]
3. Costs and financing of routine immunization: Approach and selected findings of a multi-country study (EPIC).
Brenzel L; Young D; Walker DG
Vaccine; 2015 May; 33 Suppl 1():A13-20. PubMed ID: 25919153
[TBL] [Abstract][Full Text] [Related]
4. Mapping financial flows for immunisation in Uganda 2009/10 and 2010/11: New insights for methodologies and policy.
Guthrie T; Zikusooka C; Kwesiga B; Abewe C; Lagony S; Schutte C; Marinda E; Humphreys K; Motlogelwa K; Nombewu ZC; Brenzel L; Kinghorn A
Vaccine; 2015 May; 33 Suppl 1():A79-84. PubMed ID: 25919180
[TBL] [Abstract][Full Text] [Related]
5. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
6. Costs of routine immunization and the introduction of new and underutilized vaccines in Ghana.
Le Gargasson JB; Nyonator FK; Adibo M; Gessner BD; Colombini A
Vaccine; 2015 May; 33 Suppl 1():A40-6. PubMed ID: 25919173
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
8. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
[TBL] [Abstract][Full Text] [Related]
9. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
10. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
11. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
12. Costs of routine immunization services in Moldova: Findings of a facility-based costing study.
Goguadze K; Chikovani I; Gaberi C; Maceira D; Uchaneishvili M; Chkhaidze N; Gotsadze G
Vaccine; 2015 May; 33 Suppl 1():A60-5. PubMed ID: 25919177
[TBL] [Abstract][Full Text] [Related]
13. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
[TBL] [Abstract][Full Text] [Related]
14. EPIC Studies: Governments Finance, On Average, More Than 50 Percent Of Immunization Expenses, 2010-11.
Brenzel L; Schütte C; Goguadze K; Valdez W; Le Gargasson JB; Guthrie T
Health Aff (Millwood); 2016 Feb; 35(2):259-65. PubMed ID: 26858378
[TBL] [Abstract][Full Text] [Related]
15. Uganda's increasing dependence on development partner's support for immunization - a five year resource tracking study (2012 - 2016).
Kamya C; Abewe C; Waiswa P; Asiimwe G; Namugaya F; Opio C; Ampeire I; Lagony S; Muheki C
BMC Public Health; 2021 Jan; 21(1):160. PubMed ID: 33468094
[TBL] [Abstract][Full Text] [Related]
16. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
[TBL] [Abstract][Full Text] [Related]
17. Funding gap for immunization across 94 low- and middle-income countries.
Ozawa S; Grewal S; Portnoy A; Sinha A; Arilotta R; Stack ML; Brenzel L
Vaccine; 2016 Dec; 34(50):6408-6416. PubMed ID: 28029541
[TBL] [Abstract][Full Text] [Related]
18. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
[TBL] [Abstract][Full Text] [Related]
19. Public and private donor financing for health in developing countries.
Howard LM
Infect Dis Clin North Am; 1991 Jun; 5(2):221-34. PubMed ID: 1869807
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of routine immunisation in Zambia.
Schütte C; Chansa C; Marinda E; Guthrie TA; Banda S; Nombewu Z; Motlogelwa K; Lervik M; Brenzel L; Kinghorn A
Vaccine; 2015 May; 33 Suppl 1():A47-52. PubMed ID: 25919174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
